受强制性开放获取政策约束的文章 - Toshimitsu Hamasaki了解详情
无法在其他位置公开访问的文章：2 篇
Sex Differences in Management and Outcomes of Cardioembolic Stroke: Post HOC Analyses of the RELAXED Study
T Okada, K Uchida, F Sakakibara, H Kageyama, M Yasaka, K Toyoda, ...
Journal of Stroke and Cerebrovascular Diseases 30 (4), 105613, 2021
强制性开放获取政策： US National Institutes of Health
Generalized fiducial inference for the restricted mean survival time
I Bebu, G Diao, T Hamasaki
Statistical Methods in Medical Research, 2023
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：27 篇
Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data
G Thomalla, F Boutitie, H Ma, M Koga, P Ringleb, LH Schwamm, O Wu, ...
The Lancet 396 (10262), 1574-1584, 2020
强制性开放获取政策： US National Institutes of Health, National Health and Medical Research …
The Adaptive designs CONSORT Extension (ACE) Statement: A checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design
M Dimairo, P Pallmann, J Wason, S Todd, T Jaki, J Steven A., AP Mander, ...
BMJ 369, m115, 2020
强制性开放获取政策： Cancer Research UK, UK Medical Research Council, National Institute for …
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design
M Dimairo, E Coates, P Pallmann, S Todd, S Julious, T Jaki, J Wason, ...
BMC Medicine 16, 210, 2018
强制性开放获取政策： Cancer Research UK, UK Medical Research Council, National Institute for …
Sample size determination for clinical trials with co‐primary outcomes: exponential event times
T Hamasaki, T Sugimoto, S Evans, T Sozu
Pharmaceutical Statistics 12 (1), 28-34, 2013
强制性开放获取政策： US National Institutes of Health
Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review
T Hamasaki, SR Evans, K Asakura
Journal of Biopharmaceutical Statistics 28 (1), 28-51, 2018
强制性开放获取政策： US National Institutes of Health
Sample size determination in group‐sequential clinical trials with two co‐primary endpoints
K Asakura, T Hamasaki, T Sugimoto, K Hayashi, SR Evans, T Sozu
Statistics in Medicine 33 (17), 2897-2913, 2014
强制性开放获取政策： US National Institutes of Health
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial
NA Turner, S Zaharoff, H King, S Evans, T Hamasaki, T Lodise, ...
Trials 23 (1), 1-15, 2022
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs
Group-sequential strategies in clinical trials with multiple co-primary outcomes
T Hamasaki, K Asakura, SR Evans, T Sugimoto, T Sozu
Statistics in Biopharmaceutical Research 7 (1), 36-54, 2015
强制性开放获取政策： US National Institutes of Health
A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints
T Sugimoto, T Sozu, T Hamasaki, SR Evans
Biostatistics 14 (3), 409-421, 2013
强制性开放获取政策： US National Institutes of Health
Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2 …
PD Tamma, M Souli, M Billard, J Campbell, D Conrad, DW Ellison, ...
Trials 23 (1), 1057, 2022
强制性开放获取政策： US National Institutes of Health
Improving Traditional Registrational Trial End Points: Development and Application of a Desirability of Outcome Ranking End Point for Complicated Urinary Tract Infection …
J Howard-Anderson, T Hamasaki, W Dai, D Collyar, D Rubin, S Nambiar, ...
Clinical Infectious Diseases, 2022
强制性开放获取政策： US Department of Energy, US National Institutes of Health
Interim evaluation of efficacy or futility in group‐sequential trials with multiple co‐primary endpoints
K Asakura, T Hamasaki, SR Evans
Biometrical Journal 59 (4), 703-731, 2017
强制性开放获取政策： US National Institutes of Health
Analysis of ordered composite endpoints
D Follmann, MP Fay, T Hamasaki, SR Evans
Statistics in Medicine 39 (5), 602-616, 2020
强制性开放获取政策： US National Institutes of Health
Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS)
SR Evans, D Follmann, Y Liu, T Holland, SB Doernberg, N Rouphael, ...
Clinical Infectious Diseases 68 (11), 1961-1967, 2019
强制性开放获取政策： US National Institutes of Health
Sizing clinical trials when comparing bivariate time‐to‐event outcomes
T Sugimoto, T Hamasaki, SR Evans, T Sozu
Statistics in Medicine 36 (9), 1363-1382, 2017
强制性开放获取政策： US National Institutes of Health
Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind …
EL Tsalik, NG Rouphael, RT Sadikot, MC Rodriguez-Barradas, ...
The Lancet Infectious Diseases 23 (4), 484-495, 2023
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs
Sample size considerations in clinical trials when comparing two interventions using multiple co-primary binary relative risk contrasts
Y Ando, T Hamasaki, SR Evans, K Asakura, T Sugimoto, T Sozu, Y Ohno
Statistics in Biopharmaceutical Research 7 (2), 81-94, 2015
强制性开放获取政策： US National Institutes of Health
A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection
J Howard-Anderson, W Dai, D Yahav, T Hamasaki, A Turjeman, F Koppel, ...
Open Forum Infectious Diseases 9 (6), ofac140, 2022
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定